Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Sep

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC

Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC

DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer

MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC

New Executive Director of the Duke Cancer Institute Named